In The News Posted February 8, 2020 Share Posted February 8, 2020 TARRYTOWN, N.Y., Feb. 8, 2020 /PRNewswire/ -- New data highlight importance of proactive EYLEA treatment as more than half of untreated patients in PANORAMA developed vision-threatening events over two years High-dose aflibercept development program underway with Phase 3 trials planned... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.